Clinical trials are becoming increasingly complex, particularly with
broader scopes, globalisation, changing and expanding regulatory
requirements and a greater number of players, such as contract
research organisations (CROs), sites, laboratories and vendors.
Lorie McClain at Bioclinica discusses the consequences of poor
forecasting and the great benefits of special technology tools
designed for clinical research.